Mitoxantrone-related acute myeloblastic leukaemia in a patient with metastatic hormone-refractory prostate cancer

Anti-Cancer Drugs

Volumn 18, Issue 2, 2007, Pages 233-235

  Martinez, Valérie ^a   Mir, Olivier ^a   Dômont, Julien ^a   Bouscary, Didier ^a   Goldwasser, François ^a  

^a Institut Cochin   (France)

Author keywords

Mitoxantrone; Prostate cancer; Secondary leukaemia

Indexed keywords

ANTINEOPLASTIC AGENT; CAPECITABINE; CYTARABINE; DNA TOPOISOMERASE (ATP HYDROLYSING); IDARUBICIN; IROFULVEN; MITOXANTRONE; PROSTATE SPECIFIC ANTIGEN;

ACUTE MYELOBLASTIC LEUKEMIA; ADULT; ARTICLE; BONE METASTASIS; CANCER PATIENT; CASE REPORT; CLINICAL FEATURE; CONTINUOUS INFUSION; DOSE RESPONSE; HUMAN; MALE; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PROSTATE CANCER; TREATMENT DURATION;

ANDROGENS; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; CYTARABINE; HUMANS; IN SITU HYBRIDIZATION; LEUKEMIA, MYELOCYTIC, ACUTE; MALE; MIDDLE AGED; MITOXANTRONE; NEOPLASM METASTASIS; PROSTATIC NEOPLASMS;

EID: 33845706046     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e3280113324     Document Type: Article

References (23)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ. Cancer statistics, 2006. CA Cancer J Clin 2006; 56:106-130.
2. Rini BI, Small EJ. An update on prostate cancer. Curr Opin Oncol 2001; 13:204-211.
3. Figg WD, Feuer J, Bauer KS. Management of hormone-sensitive metastatic prostate cancer. Cancer Pract 1997; 5:258-263.
4. Beedassy A, Cardi G. Chemotherapy in advanced prostate cancer. Semin Oncol 1999; 26:428-438.
5. Oh WK. Chemotherapy for patients with advanced prostate carcinoma: a new option for therapy. Cancer 2000; 88:3015-3021.
6. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351:1502-1512.
7. Petrylak DP, Tangen CM, Hussain MHA, Lara PN, Jones JA, Taplin ME, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351:1513-1520.
8. Dahut WL, Gulley JL, Arlen PM, Liu Y, Fedenko KM, Steinberg SM, et al. Randomized phase II trial of docetaxel plus thalidomide in androgenin-dependent prostate cancer. J Clin Oncol 2004; 22:2532-2539.
9. Curtis RE, Boice JD, Stovall M, Bernstein L, Grennberg RS, Flannery JT, et al. Risk of leukemia after chemotherapy and radiation treatment for breast cancer. N Engl J Med 1992; 326:1745-1751.
10. Le Deley MC, Leblanc T, Shamsaldin A, Raquin MA, Lacour B, Sommelet D, et al. Risk of secondary leukemia after a solid tumor in childhood according to the dose of epipodophyllotoxins and anthracyclines: a case-control study by the Société Francaise d'Oncologie Pédiatrique. J Clin Oncol 2003; 21:1074-1081.
11. Chaplain G, Milan C, Sgro C, Carli PM, Bonithon-Kopp C. Increased risk of acute leukemia after adjuvant chemotherapy for breast cancer: a populationbased study. J Clin Oncol 2000; 18:2836-2842.
12. Pommier Y, Goldwasser F. Toposiomerase II inhibitors: the epipodophyllotoxins, acridines, and ellipticines. In: Chabner B, Longo D, eds. Cancer Chemotherapy and Biotherapy. 4th ed. Philadelphia: Lippincott Williams & Wilkins; 2006: 451-475.
13. Harousseau JL, Cahn JY, Pignon B, Witz F, Milpied N, Delain M, et al. Comparison of autologous bone marrow transplantation and intensive chemotherapy as postremission therapy in adult acute myeloid leukaemia. The Groupe Ouest Est Leucemies Aigues Myeloblastiques (GOELAM). Blood 1997; 90:2978-2986.
14. Cohen BA, Mikol DD. Mitoxantrone treatment of multiple sclerosis: safety considerations. Neurology 2004; 63 (Suppl 6):S28-S32.
15. Lenz G, Dreyling M, Schiegnitz E, Haferlach T, Hasford J, Unterhalt M, Hiddemann W. Moderate increase of secondary hematologic malignancies after myeloablative radiochemotherapy and autologous stem-cell transplantation in patients with indolent lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group. J Clin Oncol 2004; 22:4926-4933.
16. Ng AK, Bernardo MV, Weller E, Backstrand K, Silver B, Marcus KC, et al. Second malignancy after Hodgkin disease treated with radiation therapy with or without chemotherapy: long-term risks and risk factors. Blood 2002; 100:1989-1996.
17. Andre M, Henry-Amar M, Blaise D, Colombat P, Fleury J, Miliped N, et al. Treatment-related deaths and second cancer risk after autologous stem-cell transplantation for Hodgkin's disease. Blood 1998; 92:1933-1940.
18. Micallef IN, Lillington DM, Apostolidis J, Amess JA, Neat M, Matthews J, et al. Therapy-related myelodysplasia and secondary acute myelogenous leukemia after high-dose therapy with autologous hematopoietic progenitorcell support for lymphoid malignancies. J Clin Oncol 2000; 18:947-955.
19. Deconinck E, Foussard C, Bertrand P, Cornilled L, Milpied N, Escoffre-Barbe M, et al. Value of autologous stem cell transplantation in first-line therapy of follicular lymphoma with high tumor burden: final results of the randomized GOELAMS 064 trial. Blood 2003; 102:246.
20. Neugut AI, Robinson E, Nieves J, Murray T, Tsai WY. Poor survival of treatment related acute nonlymphocytic leukemia. JAMA 1990; 264:1006-1008.
21. Harrison CN, Vaughan G, Devereux S, Linch DC. Outcome of secondary myeloid malignancy in Hodgkin's disease: the BNLI experience. Eur J Haematol 1998; 61:109-112.
22. Josting A, Wiedenmann S, Franklin J, May M, Sieber M, Wolf J, et al. Secondary myeloid leukemia and myelodysplastic syndromes in patients treated for Hodgkin's disease: a report from the German Hodgkin's Lymphoma Study Group. J Clin Oncol 2003; 21:3440-3446.
23. Dann EJ, Rowe JM. Biology and therapy of secondary leukaemias. Best Pract Res Clin Haematol 2001; 1:119-137.